


Stabilis



Methohexital sodium



Tradename

Brevimital	France, Spain
Brevital sodium	Egypt, New Zealand, United States of America
Brietal	Austria, Canada, Czech Republic, Finland, Great Britain, Hungary, Netherlands, New Zealand, Norway, Poland, Romania, Sweden, Switzerland

















Stability in solutions

?		10 mg/ml	4°C		42			531



Compatibility

		Methohexital sodium Atracurium besylate		3676
		Methohexital sodium Clindamycin phosphate		3526
		Methohexital sodium Droperidol		4009
		Methohexital sodium Erythromycin lactobionate		3674
		Methohexital sodium Esketamine		4700
		Methohexital sodium : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Methohexital sodium Fentanyl citrate		3503

		Methohexital sodium Glycopyrronium bromide		3599
		Methohexital sodium Ketamine hydrochloride		3501
		Methohexital sodium Morphine sulfate		3531
		Methohexital sodium Nicardipine hydrochloride		3941
		Methohexital sodium Nicardipine hydrochloride		3614
		Methohexital sodium Rocuronium bromide		3564
		Methohexital sodium Suxamethonium chloride		3631



Route of administration
































References

	Type	Publication
531	Journal	Beeman CS, Dembo J, Bogardus A. Stability of reconstituted methohexital sodium. J Oral Maxillofac Surg 1994 ; 52: 393-396.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
3501	Manufacturer	Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011
3503	Manufacturer	Fentanyl - Summary of product Characteristics Hameln Pharmaceuticals 2012
3526	Manufacturer	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Manufacturer	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3564	Manufacturer	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3599	Manufacturer	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercy 2013
3614	Manufacturer	Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013
3631	Manufacturer	Suxamethonium (Suxamethonium Aguetant®) - Résumé des caractéristiques du produit Aguettant 2016
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3676	Manufacturer	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014

3941	Manufacturer	Nicardipine - Summary of Product Characteristics Concordia International 2017
4009	Manufacturer	Droperidol - Résumé des Caractéristiques du Produit
4700	Manufacturer	Euphamine 251 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022



Dictionary

	General anesthetic		Injection
	Tradename		Stability in solutions
	Container		Molecule
	Concentration		Temperature
	Storage		Duration of stability
	Biosimilar		Conflicting data
	References		Not specified
	Water for Injection		Protect from light
	Day		Compatibility
	Compound		Solvent
	Unspecified incompatibility		Incompatible
	Immediate precipitation		Sodium chloride 0,9%
	Route of administration		Intravenous
	Continuous infusion		References
	Dictionary		